Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 7/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498311 | 1.00 | PIK3CD (0.45) | PIK3CDCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL92842 | 0.89 | CHRM2 (0.45) | PIK3CDCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL13662060 | 0.89 | PIK3CD (0.58) | PIK3CDCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL20713741 | 0.89 | CHRM2 (0.45) | PIK3CDCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL1002636 | 0.89 | PIK3CD (0.58) | PIK3CDCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL24633719 | 0.89 | CHRM2 (0.45) | PIK3CDCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL13748623 | 0.89 | PIK3CD (0.58) | PIK3CDCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL1002266 | 0.89 | PIK3CD (0.58) | PIK3CDCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL29058376 | 0.84 | CHRM2 (0.44) | PIK3CDCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL29770788 | 0.84 | CHRM2 (0.44) | PIK3CDCHRM2CHRM1CHRM3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | PIK3CD 902/4885CHRM2 642/4885CHRM1 468/4885 |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | PIK3CD 959/4885CHRM2 615/4885CHRM1 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.